PharmaKrysto Ltd, a biopharmaceutical company based in Scotland, UK, announces today that it has completed an exclusive global licensing deal with Rutgers University, New Jersey, …
AZD3759, AlphaBio’s lead product, is a next-generation small molecule tyrosine kinase inhibitor (TKI). It is specifically designed to treat epidermal growth factor receptor (EGFR) mutation …
Orchard Therapeutics, a leading commercial stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the …
Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the acceptance of 4 poster presentations and one podium presentation at the American Society of Clinical …
